pneumonia
frequent
infecti
complic
solid
organ
transplant
sot
occurr
posttranspl
pneumonia
advers
impact
graft
recipi
surviv
well
cost
care
sot
recipi
numer
microorgan
caus
pneumonia
sot
recipi
etiolog
result
selflimit
infect
other
caus
signific
morbid
mortal
result
vari
clinic
present
etiolog
pneumonia
sot
recipi
arriv
specif
microbiolog
diagnosi
challeng
import
optim
care
especi
complic
refractori
pneumonia
section
clinic
present
differenti
diagnosi
diagnost
test
empir
antimicrobi
treatment
pneumonia
sot
recipi
review
pathogenspecif
section
within
ast
id
guidelin
referenc
inform
regard
diagnosi
treatment
specif
pathogen
caus
pneumonia
vulner
popul
guidelin
ast
infecti
diseas
commun
practic
review
diagnosi
manag
pneumonia
posttranspl
period
clinic
present
differenti
diagnosi
pneumonia
solid
organ
transplant
recipi
review
twotier
approach
propos
base
net
state
immunosuppress
sever
present
lower
risk
opportunist
hospitalacquir
exposurespecif
pathogen
nonsever
present
empir
therapi
may
initi
close
clinic
observ
patient
respond
initi
therapi
aggress
diagnost
approach
includ
sampl
tissu
microbiolog
patholog
test
warrant
given
broad
rang
potenti
pathogen
microbiolog
diagnosi
often
key
optim
care
given
limit
literatur
compar
evalu
diagnost
approach
pneumonia
solid
organ
transplant
recipi
much
propos
diagnost
algorithm
reflect
clinic
experi
rather
evidencebas
data
serv
templat
may
modifi
accord
local
need
hold
true
suggest
empir
therapi
need
adapt
local
resist
pattern
studi
need
compar
evalu
diagnost
empir
treatment
strategi
sot
recipi
diagnosi
pneumonia
transplant
dulek
et
al
clinic
present
pneumonia
sot
recipi
highli
variabl
tradit
present
cough
increas
sputum
product
fever
alway
prompt
evalu
pneumonia
howev
frequent
subtl
symptom
predomin
diagnosi
pneumonia
reach
care
clinic
evalu
clinic
evolut
vari
rapid
indic
bacteri
viral
pathogen
subacut
chronic
present
often
seen
fungal
mycobacteri
infect
high
index
suspicion
pneumonia
essenti
sign
infect
present
solid
organ
transplant
recipi
lung
involv
evalu
transplant
patient
present
unexplain
fever
even
absenc
lungspecif
clinic
find
differenti
diagnosi
pneumonia
sot
recipi
includ
infecti
noninfecti
etiolog
tabl
understand
infecti
etiolog
patient
driven
epidemiolog
investig
transplant
otherwis
healthi
adult
pediatr
patient
earlier
era
studi
pneumonia
sot
recipi
focus
high
incid
opportunist
infect
invas
mold
infect
cytomegaloviru
cmv
improv
infect
prevent
strategi
better
diagnost
tool
newer
immunosuppress
strategi
import
communityacquir
bacteri
viral
infect
sotassoci
pneumonia
increasingli
appreci
differenti
diagnosi
pneumonia
sot
recipi
depend
upon
multitud
nonspecif
factor
includ
limit
age
time
posttranspl
net
state
immunosuppress
specif
organ
transplant
environment
exposur
site
pneumonia
acquisit
commun
vs
healthcarehospitalacquir
radiograph
infiltr
pattern
risk
pneumonia
sot
recipi
determin
degreedepth
immunosuppress
healthcar
andor
ventilatorassoci
pneumonia
frequent
diagnos
earli
posttranspl
period
two
seri
earli
onset
pneumonia
postliv
transplant
domin
bacteri
etiolog
major
gramneg
bacilli
major
pneumonia
episod
occur
later
posttranspl
occur
year
posttranspl
renal
recipi
episod
occur
month
posttranspl
multicent
point
preval
studi
type
organ
transplant
influenc
incid
time
microbiolog
spectrum
pneumonia
sot
recipi
lung
transplant
pose
uniqu
challeng
given
potenti
donorderiv
infect
recipi
airway
colon
impact
occurr
microbiolog
pneumonia
prospect
multicent
studi
pneumonia
lung
transplant
recipi
pneumonia
incid
episod
per
lung
transplant
per
year
though
bacteri
pneumonia
frequent
etiolog
fungal
array
noninfecti
etiolog
mimic
infecti
pneumonia
sot
recipi
tabl
posttranspl
lymphoprolif
diseas
ptld
may
present
lungthorac
involv
includ
pulmonari
nodul
mediastin
adenopathi
especi
lungheartlung
transplant
recipi
pulmonari
ptld
also
radiograph
mimic
infecti
etiolog
pneumonia
mtor
inhibitorinduc
pneumon
infrequ
though
potenti
sever
medic
side
effect
gener
resolv
discontinu
mtor
inhibitor
therapi
may
coexist
infecti
etiolog
includ
pjp
communityacquir
respiratori
virus
nonptld
primari
metastat
lung
cancer
also
occur
sot
recipi
complic
pulmonari
embol
pulmonari
hemorrhag
pulmonari
edema
also
report
studi
prospect
compar
diagnost
approach
pneumonia
sot
recipi
specif
diagnost
test
evalu
systemat
individu
test
perform
often
defin
healthi
subject
group
subject
varieti
immunocompromis
condit
therefor
appropri
diagnost
evalu
pneumonia
sot
recipi
highli
individu
base
local
epidemiolog
local
avail
test
practic
paramet
well
patientspecif
risk
factor
exposur
medic
histori
guidelin
diagnosi
pneumonia
group
also
inform
though
alway
specif
appli
sot
recipi
tier
approach
diagnost
evalu
pneumonia
encompass
initi
approach
follow
extens
evalu
diagnosi
remain
unclear
patient
deterior
clinic
situat
critic
specif
diagnosi
initi
suspect
respect
test
appli
order
diagnost
test
modifi
one
potenti
diagnost
approach
pneumonia
sot
recipi
outlin
figur
diagnost
evalu
sot
recipi
suspect
confirm
pneumonia
perform
use
tier
approach
pace
extent
evalu
inform
sever
acuiti
present
degre
immunosuppress
patient
risk
factorexposur
histori
strong
low
recommend
use
current
pneumonia
sever
score
sot
recipi
pneumonia
strong
low
acuiti
patient
clinic
present
use
inform
guid
differenti
diagnosi
diagnost
evalu
empir
antimicrobi
therapi
strong
low
need
contact
respiratori
isol
assess
act
upon
earli
patient
evalu
avoid
exposur
sot
recipi
patient
andor
staff
potenti
contagi
pathogen
strong
high
local
epidemiolog
respiratori
virus
particular
influenza
viru
review
consid
evalu
strong
high
initi
evalu
sot
recipi
pneumonia
includ
blood
radiolog
test
consider
given
viral
detect
nasopharynx
clinician
obtain
complet
blood
count
differenti
electrolyt
chemistri
liver
function
test
part
initi
laboratori
evalu
aid
diagnosi
de
contribut
inflammatori
marker
leukocyt
count
creactiv
protein
procalcitonin
extens
studi
tool
gener
practition
decid
whether
empir
antibiot
treatment
may
necessari
mix
result
sever
studi
evalu
util
procalcitonin
measur
detect
differenti
bacteri
infect
solid
organ
transplant
complic
review
importantli
procalcitonin
level
impact
surgeri
well
atg
administr
may
decreas
util
assay
first
week
posttranspl
laboratori
test
obtain
part
initi
evalu
perform
weak
low
done
yet
ct
scan
chest
perform
better
delin
radiolog
pattern
locat
infiltr
ident
potenti
opportun
invas
diagnost
procedur
strong
high
addit
blood
test
guid
radiograph
pattern
exposur
degre
immunosuppress
includ
antigen
andor
serolog
evalu
endem
mycos
strong
high
see
endem
fungi
section
edit
ast
id
guidelin
fungal
biomark
measur
bloodserum
galactomannan
poor
perform
characterist
sot
recipi
compar
hsct
recipi
studi
evalu
whether
perform
characterist
case
invas
test
need
obtain
diagnosi
invas
procedur
diagnost
test
sot
recipi
pneumonia
includ
bronchoscopi
bronchoalveolar
lavag
bal
transbronchi
biopsi
ctguid
biopsi
videoassist
thoracotomi
vat
lung
biopsi
open
lung
biopsi
procedur
particularli
import
diagnosi
fungal
diseas
see
aspergillu
cryptococcu
endem
fungi
emerg
fungi
section
edit
ast
id
guidelin
evalu
noninfecti
caus
malign
though
potenti
exist
achiev
diagnosi
one
method
decis
pursu
procedur
evalu
sot
recipi
pneumonia
must
balanc
procedur
risk
potenti
benefit
physician
care
sot
recipi
pneumonia
low
threshold
procedur
evalu
especi
set
patient
improv
highli
immunocompromis
diagnosi
remain
uncertain
strong
moder
bronchoalveolar
lavag
offer
opportun
obtain
microbiolog
diagnosi
either
without
transbronchi
biopsi
util
bal
sot
recipi
pneumonia
lung
infiltr
lung
nodul
evalu
sever
small
seri
microbiolog
yield
bal
studi
rang
highest
yield
patient
nosocomi
pneumonia
onset
symptom
month
posttranspl
importantli
microbiolog
yield
clearli
influenc
pretest
probabl
infect
rel
incid
infect
distinct
popul
bal
studi
list
figur
propos
complet
list
diagnost
option
extens
perform
complet
list
studi
may
need
sot
recipi
pneumonia
recommend
perform
bal
set
diffus
focal
pulmonari
infiltr
patient
failur
improv
empir
antibacteri
therapi
diagnosi
reach
noninvas
test
strong
moder
decis
proceed
bal
versu
lung
biopsi
initi
invas
test
must
highli
individu
patient
depend
clinician
riskbenefit
analysi
biopsybas
evalu
offer
abil
directli
identifi
infecti
agent
tissu
also
determin
histolog
pattern
inflamm
present
open
lung
biopsi
olb
studi
singlecent
kidney
transplant
popul
bilater
lung
infiltr
overal
olb
diagnost
yield
find
olb
result
therapeut
manag
chang
complic
frequent
olb
associ
higher
mortal
rate
similar
studi
compar
sot
nonsot
patient
diffus
lung
diseas
demonstr
therapeut
manag
chang
frequenc
percutan
ctguid
lung
biopsi
evalu
one
seri
sot
recipi
parenchym
lung
nodul
diagnost
yield
seri
biopsi
frequent
diagnos
fungal
diseas
malign
yield
highest
use
fineneedl
aspir
core
biopsi
combin
procedur
complic
occur
patient
decis
proceed
lung
biopsi
must
highli
individu
patient
depend
clinician
risk
benefit
analysi
recommend
lung
biopsi
open
vat
ctguid
set
diffus
focal
pulmonari
infiltr
patient
failur
improv
empir
antibacteri
therapi
diagnosi
reach
noninvas
test
bal
strong
moder
recommend
lung
biopsi
transbronchi
open
vat
ctguid
patient
focal
pulmonari
nodul
diagnosi
alreadi
establish
mean
due
risk
malign
includ
ptld
invas
fungal
infect
weak
low
consider
given
close
followup
serial
imag
prior
perform
invas
diagnost
procedur
case
risk
malign
andor
invas
fungal
infect
felt
low
weak
low
patient
live
geograph
area
impart
risk
endem
fungal
infect
exposur
histori
suggest
moder
high
risk
endem
fungal
infect
recommend
deferr
lung
biopsi
antigenserolog
assess
endem
fungal
infect
complet
weak
low
nonhypothesisdriven
test
broadspectrum
bacteri
pcr
base
panfung
mycobacteri
genu
pcr
univers
avail
system
studi
sot
recipi
howev
assay
may
help
patient
test
identifi
etiolog
unbias
nextgener
sequenc
may
assist
defin
specif
etiolog
avail
though
clinic
studi
need
defin
util
sequencingbas
diagnost
approach
pneumonia
stabl
patient
consid
suitabl
outpati
therapi
lower
risk
opportunist
hospitalacquir
infect
specif
pathogen
suspect
empir
therapi
cover
communityacquir
pneumonia
follow
nationalintern
guidelin
influenc
local
resist
preval
pattern
strong
low
betalactam
fluoroquinolon
fq
coverag
respiratori
pathogen
may
consid
empir
therapi
set
strong
low
practition
consid
role
drug
interact
advers
reaction
increas
antimicrobi
resist
consid
risk
benefit
fq
use
sot
recipi
consider
given
empir
coverag
intracellular
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
spp
sot
recipi
communityacquir
pneumonia
weak
low
greater
consider
given
empir
intracellular
pathogen
treatment
pediatr
sot
recipi
communityacquir
pneumonia
strong
moder
one
import
consider
select
use
empir
therapi
set
drugdrug
interact
present
macrolid
immunosuppress
agent
respiratori
fluoroquinolon
may
consid
set
high
incid
macrolid
resist
mycoplasma
spp
consider
given
abovenot
issu
consid
risk
benefit
fq
use
weak
low
sot
recipi
requir
hospit
pneumonia
combin
therapi
betalactam
agent
activ
agent
activ
intracellular
organ
mycoplasma
spp
children
legionella
spp
adult
recommend
strong
low
breadth
coverag
penicillinbas
agent
use
depend
local
resist
pattern
especi
pneumonia
whether
nosocomi
approach
warrant
cover
hospitalacquir
gramneg
pathogen
eg
recent
hospit
underli
chronic
bronchiectat
lung
diseas
presenc
prosthet
materi
fluoroquinolon
altern
set
strong
low
hospit
patient
nosocomi
ventilatorassoci
pneumonia
intern
nation
guidelin
appli
attent
local
guidelin
preval
epidemiolog
strong
moder
empir
therapi
must
adapt
new
clinic
microbiolog
find
appropri
initi
empir
therapi
measur
larg
part
patient
clinic
respons
close
monitor
includ
repeat
clinic
evalu
prerequisit
outpati
approach
feasibl
doubt
prevail
inpati
manag
favor
furthermor
empir
therapi
pneumonia
key
gap
antimicrobi
coverag
must
kept
mind
empir
regimen
optim
treat
nocardia
spp
pneumocysti
jirovecii
mycobacteri
infect
may
partial
mitig
activ
drug
use
empir
pneumonia
therapi
eg
imipenem
quinolon
oxazolidinon
addit
empir
antibacteri
regimen
clearli
provid
coverag
invas
opportunist
andor
endem
fungal
infect
clinician
care
sot
recipi
subacut
chronic
ill
present
includ
pneumonia
consid
pathogen
nocardia
tuberculosi
nontubercul
mycobacteria
endem
fungi
invas
mold
pathogen
requir
bronchoalveolar
fluid
tissu
test
diagnosi
treatment
entail
prolong
cours
antimicrobi
regimen
empir
therapi
usual
institut
prior
diagnost
test
procedur
howev
uniqu
situat
high
acuiti
inabl
perform
diagnost
procedur
empir
therapi
pathogen
may
need
diagnosi
treatment
pneumonia
sot
recipi
challeng
due
vari
clinic
present
numer
potenti
etiolog
breadth
empir
target
treatment
option
diagnost
strategi
must
consid
numer
factor
includ
posttranspl
time
degre
immunosuppress
environmentalcommunityhospit
exposur
season
epidemiolog
empir
treatment
larg
part
determin
local
epidemiolog
resist
pattern
novel
diagnost
techniqu
futur
prospect
studi
continu
impact
diagnosi
treatment
pneumonia
sot
recipi
author
declar
conflict
interest
